PHIO - Phio Pharmaceuticals Corp.
IEX Last Trade
2.02
0.040 1.980%
Share volume: 1,223
Last Updated: Thu 26 Dec 2024 08:01:18 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$1.98
0.04
2.02%
Fundamental analysis
26%
Profitability
25%
Dept financing
6%
Liquidity
50%
Performance
25%
Performance
5 Days
-1.35%
1 Month
-12.35%
3 Months
-38.38%
6 Months
214.29%
1 Year
191.01%
2 Year
-48.85%
Key data
Stock price
$2.02
DAY RANGE
$1.94 - $2.08
52 WEEK RANGE
$0.58 - $6.04
52 WEEK CHANGE
$187.96
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Geert C. PhD
Region: US
Website: phiopharma.com
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: phiopharma.com
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. Company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT) PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression.
Recent news